Published in Proc Natl Acad Sci U S A on February 11, 2008
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol (2013) 3.02
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer (2008) 2.52
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol (2011) 2.10
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A (2012) 2.04
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature (2014) 1.61
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res (2015) 1.53
Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α. Structure (2011) 1.48
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol (2009) 1.47
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A (2009) 1.46
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res (2009) 1.45
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α. FEBS J (2015) 1.38
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun (2015) 1.35
PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev (2009) 1.32
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
Activating mutations of TOR (target of rapamycin). Genes Cells (2011) 1.31
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget (2011) 1.26
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 1.26
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene (2013) 1.23
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene (2012) 1.22
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet (2012) 1.19
The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol (2010) 1.16
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun (2016) 1.15
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene (2011) 1.14
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol (2014) 1.13
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res (2010) 1.10
Retroviral oncogenes: a historical primer. Nat Rev Cancer (2012) 1.10
Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun (2014) 1.09
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med (2015) 1.09
Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul (2012) 1.05
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res (2013) 1.03
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget (2016) 1.02
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res (2013) 1.01
Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol (2013) 1.01
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res (2015) 1.01
Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol (2013) 1.01
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One (2013) 0.99
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol (2013) 0.98
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res (2010) 0.97
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res (2015) 0.96
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res (2014) 0.94
Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. Nat Genet (2015) 0.94
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res (2014) 0.93
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev (2012) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol (2013) 0.89
PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) (2015) 0.88
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol (2014) 0.88
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis (2013) 0.87
Membrane environment exerts an important influence on rac-mediated activation of phospholipase Cγ2. Mol Cell Biol (2011) 0.87
Structural effects of oncogenic PI3Kα mutations. Curr Top Microbiol Immunol (2010) 0.87
Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci (2014) 0.86
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. Proteins (2009) 0.86
Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. PLoS Comput Biol (2014) 0.86
Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase. PLoS One (2013) 0.86
Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.85
Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol (2015) 0.85
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat (2014) 0.85
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes (2014) 0.85
Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev (2014) 0.84
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis (2013) 0.84
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor. Mol Cancer Ther (2013) 0.83
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res (2013) 0.83
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Mol Cancer Res (2015) 0.83
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell (1991) 5.65
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J (1996) 3.99
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (1999) 3.81
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell (2000) 3.68
Oncogenic PI3K and its role in cancer. Curr Opin Oncol (2006) 3.61
Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res (2005) 3.19
Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science (1998) 3.17
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A (1998) 2.99
Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol (2004) 2.59
Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol Sci (2003) 2.35
Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer (2005) 2.06
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J (2008) 1.79
Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1.71
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem (2000) 1.71
Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol (1998) 1.68
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem (2005) 1.57
PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol (2005) 1.43
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res (2005) 1.59
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther (2011) 1.41
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 1.36
100 years of Rous sarcoma virus. J Exp Med (2011) 1.24
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol (2005) 1.20
Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17
PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol (2010) 1.16
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene (2003) 1.16
Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle (2010) 1.11
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11
Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A (2003) 1.09
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A (2004) 1.01
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
MafA has strong cell transforming ability but is a weak transactivator. Oncogene (2003) 0.96
Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene (2003) 0.96
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep (2008) 0.95
An essential role for protein synthesis in oncogenic cellular transformation. Oncogene (2004) 0.94
Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene (2002) 0.94
Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. J Am Chem Soc (2009) 0.93
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. J Am Chem Soc (2011) 0.93
Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol Pharmacol (2009) 0.90
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. J Am Chem Soc (2004) 0.88
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget (2010) 0.88
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Mol Ther Nucleic Acids (2013) 0.87
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87
Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer (2009) 0.87
Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res (2009) 0.86
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer (2010) 0.84
Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle (2011) 0.83
Progress in breast cancer research. Proc Natl Acad Sci U S A (2012) 0.82
Cell entry by non-enveloped viruses. Curr Top Microbiol Immunol (2010) 0.81
Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle (2011) 0.81
Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods Enzymol (2008) 0.81
Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene (2003) 0.80
The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene (2003) 0.80
MYCNOS functions as an antisense RNA regulating MYCN. RNA Biol (2015) 0.79
v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77
The classic: integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts: (RNA tumor viruses/reassociation kinetics/duck cells). 1973. Clin Orthop Relat Res (2008) 0.75
RICHARD BING: 12 OCTOBER 1909 - 8 NOVEMBER 2010. Proc Am Philos Soc (2014) 0.75